CT103A
- Generic Name
- CT103A
- Drug Type
- Biotech
- Background
CT103A is an investigational BCMA-targeted genetically modified autologous T-cell immunotherapy.
A Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in Patients With Relapsed/Refractory Extramedullary Multiple Myeloma
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2022-05-24
- Lead Sponsor
- Chunrui Li
- Target Recruit Count
- 20
- Registration Number
- NCT05201118
- Locations
- 🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hu Bei, China
A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)
- First Posted Date
- 2021-10-04
- Last Posted Date
- 2021-11-23
- Lead Sponsor
- Nanjing IASO Biotechnology Co., Ltd.
- Target Recruit Count
- 132
- Registration Number
- NCT05066646
- Locations
- 🇨🇳
The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
🇨🇳Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
🇨🇳The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
Early Phase 1
Recruiting
- Conditions
- Idiopathic Inflammatory MyopathiesNeuromyelitis Optica Spectrum DisorderAutoimmune Diseases of the Nervous SystemMyasthenia GravisChronic Inflammatory Demyelinating PolyradiculoneuropathyPOEMS SyndromeAutoimmune DiseasesMultiple SclerosisAutoimmune EncephalitisMyelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
- Interventions
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT04561557
- Locations
- 🇨🇳
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath